Tradipitant: Phase II data

Top-line data from the double-blind, German Phase II VP-VLY-686-2101 trial in 69 atopic dermatitis patients with chronic pruritus showed that once-daily 100 mg oral tradipitant given in the evening missed the primary endpoint of improving VAS scores for itch from baseline to week 4 vs. placebo. Vanda said there were no significant differences observed between the treatment groups due to a high placebo effect. Specifically, tradipitant improved the endpoint by 40.5 mm from baseline to week 4 vs. 36.5 mm for placebo (p<0.0001 for both compared to baseline). ...